Zobrazeno 1 - 10
of 134
pro vyhledávání: '"David J. Heal"'
Publikováno v:
Frontiers in Psychiatry, Vol 15 (2024)
Various countries and US States have legalized cannabis, and the use of the psychoactive1 and non-psychoactive cannabinoids is steadily increasing. In this review, we have collated evidence from published non-clinical and clinical sources to evaluate
Externí odkaz:
https://doaj.org/article/351461b43e3f4fb2873ef3a0c74eab5b
Publikováno v:
Journal of Psychopharmacology. 37:33-44
Background: Psychedelics are an increasingly active area of research and pharmaceutical development. This includes abuse potential assessment to better understand their pharmacological mechanisms and effects and guide controlled substance regulation.
Publikováno v:
Current topics in behavioral neurosciences. 57
Since the landmark MTA (Multimodal Treatment of ADHD) trial unequivocally demonstrated the efficacy of methylphenidate, catecholaminergic drugs, especially stimulants, have been the therapeutic mainstay in treatment of Attention-Deficit Hyperactivity
Publikováno v:
Journal of Psychopharmacology (Oxford, England)
Background: α7 Nicotinic acetylcholine receptors are implicated in the reinstatement of drug-seeking, an important component of relapse. We showed previously that the α7 nicotinic acetylcholine receptor antagonist, methyllycaconitine, specifically
Autor:
Jack E. Henningfield, Marion A. Coe, Roland R. Griffiths, Sean J. Belouin, Ann Berger, Allison R. Coker, Sandra D. Comer, David J. Heal, Peter S. Hendricks, Charles D. Nichols, Frank Sapienza, Frank J. Vocci, Farah Z. Zia
Publikováno v:
Neuropharmacology. 218
New medicines containing classic hallucinogenic and entactogenic psychedelic substance are under development for various psychiatric and neurological disorders. Many of these, including psilocybin, lysergic acid diethylamide (LSD), and 3,4-methylened
Autor:
Colleen Synan, Carrie Bowen, David J. Heal, Christelle Froger-Colléaux, Patrick M. Beardsley, Nina Dedic, Seth C. Hopkins, Una Campbell, Kenneth S. Koblan
Publikováno v:
Drug and alcohol dependence. 231
Ulotaront (SEP-363856) is a trace amine-associated receptor 1 (TAAR1) agonist with 5-hydroxytryptamine type 1A (5-HT1A) agonist activity that is currently in Phase 3 clinical development for the treatment of schizophrenia. Unlike available antipsycho
Publikováno v:
Journal of Psychopharmacology. 33:383-391
Background: Samidorphan is a novel μ-opioid antagonist with low intrinsic activity at κ- and δ-opioid receptors. Aims: Because samidorphan is central nervous system-active, we investigated whether samidorphan (13.6, 40.8, 68 μg/kg/injection) serv
Autor:
David J, Heal, Jane, Gosden
Publikováno v:
International journal of obesity (2005). 46(4)
Binge-eating disorder (BED) is the commonest eating disorder and an important causal factor in obesity. Lisdexamfetamine is the only approved pharmacological treatment. Many drugs have been clinically evaluated and several were described as potential
Publikováno v:
Journal of Psychopharmacology. 30:662-675
Compulsive and perseverative behaviour in binge-eating, female, Wistar rats was investigated in a novel food reward/punished responding conflict model. Rats were trained to perform the conditioned avoidance response task. When proficient, the paradig
Publikováno v:
Journal of Pharmacological and Toxicological Methods. 105:106704